A lack of data prevents endocrinologists from fully understanding the long-term risks of therapy in this patient population.
Outside of hormone therapy, endocrinologists reported having low confidence in their knowledge about caring for transgender patients.
Women in the menopausal transition and early postmenopause are at higher risk for depressive symptoms and negative mood than those in late postmenopause.
Menopausal status is associated with accelerated lung function decline.
In postmenopausal women taking hormone therapy, risk for death from vascular dementia appeared to be reduced.
An international survey shows that women with polycystic ovary syndrome are dissatisfied with the information they receive and the length of time to diagnosis.
Starting testosterone treatment is associated with an increased risk of venous thromboembolism (VTE), peaking within 6 months and declining thereafter.
Electro-acupuncture appeared to be as effective as paroxetine for improving sleep in breast cancer survivors with hot flashes.
Men treated with implantable testosterone pellets have a statistically significant increase in mean hematocrit, but it is unlikely to be clinically relevant.
The FDA recently approved Intrarosa (prasterone) for moderate to severe pain during sexual intercourse due to menopause.
The use of menopausal hormone therapy was associated with improved bone mineral density and better bone microarchitecture.